PRAX Stock Summary and Trading Ideas (Praxis Precision Medicines | NASDAQ:PRAX)

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Praxis Precision Medicines trades on the NASDAQ stock market under the symbol PRAX.

As of December 5, 2025, PRAX stock price climbed to $249.01 with 2,049,477 million shares trading.

PRAX has a beta of 2.02, meaning it tends to be more sensitive to market movements. PRAX has a correlation of 0.05 to the broad based SPY ETF.

PRAX has a market cap of $6.23 billion. This is considered a Mid Cap stock.

Last quarter Praxis Precision Medicines reported $0 in Revenue and -$3.36 earnings per share. This fell short of revenue expectation by $-59,440 and exceeded earnings estimates by $.11.

In the last 3 years, PRAX traded as high as $277.44 and as low as $11.85.

The top ETF exchange traded funds that PRAX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.

PRAX has outperformed the market in the last year with a price return of +235.6% while the SPY ETF gained +14.0%. PRAX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +440.3% and +51.8%, respectively, while the SPY returned +5.8% and +5.0%, respectively.

PRAX support price is $178.55 and resistance is $201.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRAX shares will trade within this expected range on the day.